Proteinopathies, a core concept for understanding and ultimately treating degenerative disorders?

• Published in: European neuropsychopharmacology 2015-05, Vol.25 (5), p.713-724
• Main Author: Bayer, Thomas A
• Format: Article
• Language: English
• Subjects: Amyloid; Animals; Clinical trial; Humans; Immunization; Internal Medicine; Neurodegenerative Diseases - drug therapy; Neurodegenerative Diseases - pathology; Neurodegenerative Diseases - physiopathology; Proteinopathy; Proteostasis Deficiencies - drug therapy; Proteostasis Deficiencies - pathology; Proteostasis Deficiencies - physiopathology; Psychiatry
• ISSN: 0924-977X; 1873-7862
• DOI: 10.1016/j.euroneuro.2013.03.007

Abstract The current review covers proteinopathies an umbrella term for neurodegenerative disorders that are characterized by the accumulation of specific proteins within neurons or in the brain parenchyma. Most prevalent examples for typical proteinopathies are Alzheimer's disease and Parkinson's disease. In healthy brain, these proteins are unstructured as a monomer, serving most likely as the physiological form. In a disease condition, the unstructured proteins experience a conformational change leading to small oligomers that eventually will aggregate into higher order structures. Prion disease is an exception within the family of proteinopathies as the aggregated prion protein is highly infectious and can self-aggregate and propagate. Recent reports might implicate a prion-like spread of misfolded proteins in Alzheimer's and Parkinson's disease; however there are evident differences in comparison to prion diseases. As proteinopathies are caused by the aggregation of disease-typical proteins with an ordered structure, active and passive immunization protocols have been used to expose model systems to therapeutic antibodies that bind to the aggregates thereby inhibiting the prolongation into higher ordered fibrils or dissolving the existing fibrillar structure. While most of the immunization treatments have been only carried out in preclinical model systems overexpressing the disease-relevant aggregating protein, other approaches are already in clinical testing. Taking the core concept of proteinopathies with conformationally altered protein aggregates into account, immunization appears to be a very promising therapeutic option for neurodegenerative disorders.